Catalyst Dossier · compiled by CeliA 🧫

Bausch Health Companies Inc. (BHC)

Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Bausch Health Companies Inc. (BHC) is a diversified Canadian pharmaceutical company with commercial operations spanning gastroenterology, dermatology, neuroscience, and international pharmaceuticals. The company generated $10.3B in revenue in 2025 and returned to GAAP net profitability, but carries $20.4B in net debt against a $1.8B market cap, making the equity a highly leveraged residual claim on the underlying business. The next disclosed catalyst is a Q2 2026 earnings release on July 29, 2026.

The catalyst path

2026-07-29Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Budesonide MMX®	Phase 3	Ulcerative Colitis
Viramidine	Phase 3	Chronic Hepatitis C
IDP 121 Lotion	Phase 3	Acne
SP-333 1 mg	Phase 2	Constipation
Taribavirin	Phase 2	Chronic Hepatitis C
IDP-118 Vehicle Cream	Phase 2	Psoriasis
Larsucosterol	Phase 3	Hepatitis
Methylnaltrexone (MOA-728)	Phase 3	Post Operative Bowel Dysfunction
Bisacodyl	Phase 3	Chronic Idiopathic Constipation
Ribavirin	Phase 3	Chronic Hepatitis C
IDP-121 Lotion	Phase 3	Acne
SC MNTX	Phase 2	Bowel Dysfunction
pradefovir mesylate	Phase 2	Hepatitis B, Chronic
Low Dose Rifaximin ER	Phase 2	Sickle Cell Disease
open-label rifaximin	Phase 3	Irritable Bowel Syndrome With Diarrhea
Plecanatide	Phase 3	Chronic Idiopathic Constipation
IV Methylnaltrexone	Phase 2	Healthy Volunteers
5 ASA, enemas, suppositories, corticosteroids	Phase 3	Ulcerative Colitis
ACYC	Phase 3	Acne
SC Methylnaltrexone (MNTX)	Phase 3	Terminal Illness

Price & technical context

3-month

-12.2%

6-month

-29.9%

12-month

-30.6%

52-wk range

$4.67–$8.34

vs 50-day MA

-7.2%

vs 200-day MA

-18.4%

Realized vol

55.0%

Max drawdown

-55.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BHC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.